Skip to content

STEMLINE THERAPEUTICS INC: 10-Q filed 2015-08-10

What STEMLINE THERAPEUTICS INC reported in its quarterly report filed 2015-08-10 (fiscal Q2 2015): 22 published measures, 63 facts as tagged in accession 0001104659-15-058322.

This filing

Form
10-Q (quarterly report)
Filed
2015-08-10
Fiscal period
fiscal Q2 2015
Accession
0001104659-15-058322 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All STEMLINE THERAPEUTICS INC filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2015-06-30111,425,696USD
At 2014-12-3160,494,992USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2015-06-306,638,638USD
At 2014-12-315,081,841USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2015-06-30104,787,058USD
At 2014-12-3155,413,151USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2015-06-3013,933,233USD
At 2014-12-3125,007,217USD
At 2014-06-3021,160,428USD
At 2013-12-3144,200,420USD

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2015-06-30-78,026,920USD
At 2014-12-31-60,195,741USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2015-06-30153,333USD
At 2014-12-31230,000USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2015-01-01 to 2015-06-302,732,902USD181
2014-01-01 to 2014-06-302,022,098USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2015-04-01 to 2015-06-30-10,230,606USD91
2015-01-01 to 2015-06-30-17,954,729USD181
2014-04-01 to 2014-06-30-6,057,172USD91
2014-01-01 to 2014-06-30-15,099,311USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2015-06-3056,095,175USD
At 2014-12-3155,620,172USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2015-06-305,844,926USD
At 2014-12-314,473,842USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2015-04-01 to 2015-06-3010,352,035USD91
2015-01-01 to 2015-06-3018,197,587USD181
2014-04-01 to 2014-06-306,128,601USD91
2014-01-01 to 2014-06-3015,241,740USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2015-04-01 to 2015-06-308,199,397USD91
2015-01-01 to 2015-06-3014,234,884USD181
2014-04-01 to 2014-06-304,090,590USD91
2014-01-01 to 2014-06-3011,207,446USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2015-06-3017,954,883shares
At 2014-12-3113,285,232shares

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2015-06-3014,061USD
At 2015-03-3136,006USD
At 2014-12-313,000USD
At 2014-06-307,919USD
At 2014-03-31-9USD
At 2013-12-31-43,775USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2015-06-30306,667USD
At 2014-12-31230,000USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2015-06-305,844,926USD
At 2014-12-314,473,842USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2015-06-302,224,697USD
At 2014-12-311,636,808USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2015-04-01 to 2015-06-30-10,175,661USD91
2015-01-01 to 2015-06-30-17,820,118USD181
2014-04-01 to 2014-06-30-6,004,770USD91
2014-01-01 to 2014-06-30-14,960,931USD181

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2015-04-01 to 2015-06-30-10,153,716USD91
2015-01-01 to 2015-06-30-17,831,179USD181
2014-04-01 to 2014-06-30-6,012,698USD91
2014-01-01 to 2014-06-30-15,012,625USD181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2015-04-01 to 2015-06-302,152,638USD91
2015-01-01 to 2015-06-303,962,703USD181
2014-04-01 to 2014-06-302,038,011USD91
2014-01-01 to 2014-06-304,034,294USD181

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2015-04-01 to 2015-06-3038,333USD91
2015-01-01 to 2015-06-3076,667USD181
2014-04-01 to 2014-06-3038,333USD91
2014-01-01 to 2014-06-3076,666USD181

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2015-01-01 to 2015-06-3064,106,372USD181

Inspect the source

Entity
STEMLINE THERAPEUTICS INC / CIK 0001264587
Captured
SEC response SHA-256
4bc563f579ac3611fca3a4b0f91dded31bf19c0e78ed6a10086fa540610de496

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001264587.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))